Andrew KeithMar 10, 2022Basilea - Refocusing on anti-infectives Our research reported published today examines Basilea's decision to concentrate its efforts on anti-infectives and the associated...
Brian WhiteMar 8, 2022Diurnal Group - SMC decision another hurdle to jumpThe decision by the Scottish Medicines Consortium not to recommend automatic reimbursement of Efmody in NHS Scotland complicates Efmody's...
Brian WhiteFeb 15, 2022Basilea - Strategic repositioningThe financial result at Basilea reflects a strong performance from the anti-infectives portfolio and Cresemba in particular as previously...
Andrew KeithFeb 14, 2022Diurnal Group - The AI and TRT opportunitiesOur research report, published today, examines the prospects for Efmody in the $1.9bn European adrenal insufficiency market. We also...
Brian WhiteFeb 10, 2022Diurnal Group - Efmody moving into larger AI disorderWhile all eyes have been on the commercial progress of Efmody in the rare congenital adrenal hyperplasia (CAH) disorder, post-approval in...
Brian WhiteJan 26, 2022Diurnal Group - Trading update ahead of R&D dayDiurnal has provided a trading update this morning to end December 2021, as the company moves to a calendar year-end from its previous...